Back to Alzheimers Disease
NCT05731440
NCT05731440
Who may be able to join
Who might be able to join this trial:
- Men or women of any race
- Adults aged 18 or older
- People who are generally healthy, or people who have been diagnosed with Alzheimer's disease
Who may not be able to join:
- People who have had an allergic reaction to the imaging agent 18F-Fluselenamyl or any of its ingredients
- People who have had an allergic reaction to the imaging agent 11C-PIB or any of its ingredients
- People who are not able to give written consent themselves and do not have a legally authorized representative (such as a guardian) who can do so on their behalf
- People who are unwilling or unable to receive injections as part of PET scan procedures
- People who are unwilling or unable to have an MRI scan (confirm with trial site regarding which parts of the study this applies to)
- People with a health condition that, in the doctor's opinion, could put them at risk, make the study procedures too difficult to tolerate, or affect the results — for example, serious kidney or liver problems, or advanced cancer
- Women who are currently pregnant or breastfeeding
- People who have taken part in other research studies involving radioactive substances within the past 12 months, where the combined radiation exposure would exceed the limits set by U.S. federal regulations
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Active, Not Recruiting
Phase
Not Applicable
Sponsor
Washington University School of Medicine
Registry
clinicaltrials_gov
Start date
18 November 2022
Est. completion
1 December 2027
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
To determine the safety of the tracer [18F]-Fluselenamyl for PET Imaging.; PET imaging of [18F]-Fluselenamyl in healthy normal control participants and human participants with mild cognitive impairment of Alzheimer's dementia.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.